Subscribe
Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
ICER Draft Flags High Cost of New Hypertension Drug Class
OCTOPUS Trial Aims to Speed Access to Rare Sarcoma Drugs
Senate Unveils Sweeping Bill to Reform 340B Drug Program
